ASSESSMENT OF HEMODYNAMICS SYMPTOMATOLOGY AND BIOCHEMICAL MARKERS OF NPR1 SIGNALING IN HEALTHY VOLUNTEERS AND PATIENTS WITH POSTURAL ORTHOSTATIC TACHYCARDIA SYNDROME (POTS) AND PATIENTS WITH NEUROGENIC ORTHOSTATIC HYPOTENSION (NOH)
The primary objective of the study is to assess the magnitude and variabilityof orthostatic hemodynamic changes in participants with POTS and inparticipants with nOH in a head up tilt table test (HUT).This is a non-interventional study to evaluate the performance of differenthemodynamic assessments, wearable devices, biomarkers, and novelelectronic clinical outcome assessments (eCOAs) in healthy participants andparticipants with POTS and with nOH. The study consists of a screeningperiod, a testing period, which includes two in-clinic visits and anambulatory period, and an end of study (EOS) visit.
Assessment of immunological and vascular dysfunction in neuropsychiatric post-acute sequelae of SARS-CoV-2 using TSPO PET and MRI
The overarching goal of this study is to develop PET/MR techniques for the diagnosis of neuropsychiatric post-acute sequelae (PASC) of SARS-CoV-2. Our central hypothesis is that immunological and cerebrovascular dysfunction after acute SARS-CoV-2 infections mediate neuropsychiatric PASC (NP-PASC).
Association between surrogates of arterial stiffness and urinary EDC in adolescents and young adults with Type 1 and Type 2 diabetes compared to age matched healthy adolescents.
Association between surrogates of arterial stiffness and urinary EDC in adolescents and young adults with Type 1 and Type 2 diabetes compared to age matched healthy adolescents.2. Introduction:Diabetes is one of the leading chronic diseases in youth(1), and its incidence has been increasing worldwide(2). About 208,000 Americans under age 20 are estimated to have diagnosed diabetes (Type 1 {T1DM} or Type 2 {T2DM}), which constitutes about 0.25% of population. The SEARCH study for Diabetes incidence in youth reported the burden of diabetes in youth
ASSURE: An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects with Primary Biliary Cholangitis (PBC)
This is an open label, uncontrolled, international multicenter long-term observational study. The study will include subjects who participated in a previous PBC study with seladelpar (CB8025-21629, CB8025-31735, or CB8025-21838) or future PBC studies with seladelpar that allow rollover into CB8025-31731, allowing their treatment to continue. Subjects who were previously on placebo in CB8025-31735 can choose to participate in this study as long as they meet eligibility criteria.Qualified subjects will receive 10 mg seladelpar. Subjects with noted tolerability issues may receive seladelpar 5 mg if in the opinion of the Investigator, that would be the appropriate starting dose. Subjects on 5 mg may be up-titrated to 10 mg after a period of clinical stability if the Investigator deems it medically appropriate and after consultation with the Medical Monitor. Subjects can be down-titrated from 10 mg to 5 mg throughout the study for reasons of safety or tolerability. They can also be re-challenged with 10 mg if the reason for prior down-titration has resolved. Treatment can also be re-initiated after dose interruption if it is agreed to be medically appropriate by consultation between the Investigator and Medical Monitor. Potential adjustment of doses for safety or tolerability will be managed as outlined in the study protocol. Subjects will continue ursodeoxycholic acid (UDCA) intake in accordance with their prescribed dose.Subjects will be evaluated for pruritus and QoL throughout the duration of study participation.Subjects will be regularly evaluated for PBC clinical outcomes. Subjects who meet any PBC clinical outcome per the study protocol will discontinue seladelpar.Subjects who discontinue seladelpar anytime during the treatment period will be asked to stay in the study to collect PBC clinical outcomes.The primary objective of the study is to evaluate the long-term safety and tolerability of seladelpar.
Asthma | NYU Langone Health
NYU Langone pulmonologists offer treatment to manage asthma, a common condition that can cause difficulty breathing.
Asthma in Children | NYU Langone Health
Doctors at Hassenfeld Children’s Hospital at NYU Langone help children manage asthma, a lung condition that can make breathing difficult.
Asthma Program | NYU Langone Health
Doctors at NYU Langone's Asthma Program offer asthma care to adults.
Asthma Program Doctors | NYU Langone Health
Find a doctor at the Asthma Program at NYU Langone.
At-Home Therapies for Eczema & Dermatitis | NYU Langone Health
NYU Langone doctors recommend avoiding substances that trigger eczema and dermatitis. Bleach baths and sun therapy may also relieve symptoms.
Athletic Training Services | NYU Langone Health
NYU Langone athletic trainers provide services to high school, university, youth league, and professional sports teams and performing arts groups.